RAS Clinical Trials

373 recruitingLast updated: June 18, 2026

There are 373 actively recruiting ras clinical trials across 52 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, Houston, Texas, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


RAS Trials at a Glance

373 actively recruiting trials for ras are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Not Applicable with 138 trials, with the heaviest enrollment activity in Boston, Houston, and New York. Lead sponsors running ras studies include Tanta University, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Treatments under study

About RAS Clinical Trials

Looking for clinical trials for RAS? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new RAS trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about RAS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 373 trials

Recruiting
Phase 2

Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

Weight GainHealthy VolunteerMetabolic Effects+1 more
National Institute of Allergy and Infectious Diseases (NIAID)120 enrolled1 locationNCT05652478
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Pancreatic CancerHereditary Breast and Ovarian CancerHodgkin Lymphoma+43 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Phase 2

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS
Verastem, Inc.180 enrolled8 locationsNCT07644559
Recruiting
Phase 1

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled35 locationsNCT07094113
Recruiting

Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies

Noonan SyndromeCardiofaciocutaneous SyndromeCostello Syndrome+3 more
National Cancer Institute (NCI)500 enrolled2 locationsNCT04888936
Recruiting

Diagnosis and Treatment of Leishmania Infections

LeishmaniasisSkin Diseases, ParasiticEuglenozoa Infections+1 more
National Institute of Allergy and Infectious Diseases (NIAID)289 enrolled1 locationNCT00344188
Recruiting
Not Applicable

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

Breast CancerAnthracycline Related Cardiotoxicity in Breast CancerTrastuzumab+1 more
Virginia Commonwealth University30 enrolled3 locationsNCT07426913
Recruiting
Phase 1Phase 2

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals40 enrolled1 locationNCT07468071
Recruiting

Intraoperative Driving Pressure and Postoperative Lung Ultrasound Score in Robot-Assisted Radical Prostatectomy

Prostatic NeoplamsMechanical VentilationPostoperative Pulmonary Complications (PPCs)+2 more
Ankara Etlik City Hospital76 enrolled1 locationNCT07610824
Recruiting
Phase 1Phase 2

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled7 locationsNCT06239272
Recruiting
Phase 1

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

RAS MutationSolid Tumors (Phase 1)
Adlai Nortye Biopharma Co., Ltd.118 enrolled3 locationsNCT07252479
Recruiting

Host Response to Infection and Treatment in Filarial Diseases

HelminthiasisFilariasisParasitic Infection+2 more
National Institute of Allergy and Infectious Diseases (NIAID)500 enrolled1 locationNCT00001230
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non-small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche600 enrolled251 locationsNCT06793215
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Not Applicable

Intravascular Ultrasound for Peripheral Artery Disease Revascularization

Chronic Limb Threatening IschemiaPeripheral Arterial Disease(PAD)Restenosis+2 more
Hamilton Health Sciences Corporation772 enrolled2 locationsNCT06979284
Recruiting
Phase 2

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

MCRCMSS Metastatic Colorectal CancerRas-mutated Metastatic Colorectal Cancer
Oncolytics Biotech60 enrolled3 locationsNCT07446322
Recruiting
Phase 1

A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

KRAS P.G12D
D3 Bio (Wuxi) Co., Ltd42 enrolled5 locationsNCT07456046
Recruiting

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Immune System DiseasesEosinophiliaHelminthiasis+2 more
National Institute of Allergy and Infectious Diseases (NIAID)800 enrolled1 locationNCT00001406